2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Head and Neck Cancer Metastatic: new trials by email Literature Review of Head and Neck Cancer Metastatic trials Research Report on Head and Neck Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers Fludarabine, Cyclophosphamide, NEXI-003 T cells - Oropharyngeal Cancer, Human Papilloma Virus | Phase 1 | Not yet recruiting | NexImmune Inc. | 36 | 2025-03-31 | 2024-01-16 |
| Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic | Recruiting | National Taiwan University Hospital | 30 | 2025-01-01 | 2026-02-24 | |
| Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Pembrolizumab, Tadalafil - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | University of California, San Diego | 7 | 2020-04-07 | 2026-02-12 |
| Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN Nivolumab 480mg and surgical resection - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 26 | 2019-07-08 | 2024-11-21 |
| A Study of ADXS-NEO Expressing Personalized Tumor Antigens ADXS-NEO, Pembrolizumab - Colon Cancer Metastatic, Head and Neck Cancer Metastatic | Phase 1 | Terminated | Advaxis, Inc. | 13 | 2018-03-28 | 2023-02-24 |
| Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT) - Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 21 | 2015-11-01 | 2026-07-14 |
Head and Neck Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (4) · Neoplasm Metastasis (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Melanoma (1) · Mouth Neoplasms (1) · Neoplasms (1) · Neoplastic Cells, Circulating (1) · Oropharyngeal Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Pyridoxine-dependent epilepsy (1) · Recurrence (1)
Neoplasms by Site (6) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Carcinoma (4) · Carcinoma, Squamous Cell (4) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Stomatognathic Diseases (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1)
pembrolizumab (2) · Cisplatin (1) · Cyclophosphamide (1) · MD1 (1) · Nivolumab (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · Tadalafil (1) · fludarabine (1) · fludarabine phosphate (1)
Advaxis, Inc. (1) · Dana-Farber Cancer Institute (1) · National Taiwan University Hospital (1) · NexImmune Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of California, San Diego (1)
United States (4) · Taiwan (1)
Jonathan Schoenfeld, MD, MPH (1) · Joseph Califano (1) · Tanguy Lim-Seiwert, MD (1)